# Cabaletta Bio Inc. (CABA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.47, market value $588 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cabaletta Bio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -26.2%** (5-yr avg -146.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -149.8%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 10.3%**. Earnings per share rose 10.3%.

## Financial health
- **Current ratio: 2.77** (quick 2.77). Current assets cover the next year's liabilities 2.77 times.

## Dividends
- **Dividend: none**. Cabaletta Bio Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Cabaletta Bio Inc.; the consensus is strong_buy, with an average price target of $13.25 (+282% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 125.3%** (YTD 58.4%, 3-mo 6.8%). The shares are up 125.3% over twelve months including dividends.
- **From 52-week high: -18.0%** (113.5% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 64**. An RSI of 64 is neutral.
- **Beta (1 yr): 1.74** (volatility 99%). Beta of 1.74 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CABA · Page: https://foliofundamentals.com/stocks/caba

Not investment advice.